FIGS Inc. (NYSE: FIGS)

Direct-to-consumer healthcare apparel leader • Founded 2013 • Santa Monica, CA

Key Finding: FIGS has demonstrated strong recent operational momentum with Q2 2026 revenue growth of 28.8% YoY and raised full-year guidance, supported by a loyal customer base of over 3 million active users, though the stock has experienced significant historical volatility since its 2021 IPO.

Company Overview & History

Official IR Overview →

Overview (Fact)

FIGS, Inc., together with its subsidiary FIGS Canada, Inc., operates as a direct-to-consumer healthcare apparel and lifestyle company. It designs and sells scrubwear, non-scrubwear (outerwear, underscrubs, footwear, compression socks, lab coats, loungewear), sports apparel, and accessories primarily to healthcare professionals via its website, mobile app, B2B channels, and limited retail stores. Source: Company profile

  • Headquarters: Santa Monica, California
  • Employees: Approximately 388 (as of recent filings)
  • Market Focus: Premium, technically advanced apparel emphasizing fit, function, durability, and style for healthcare workers

History (Fact)

  • 2013: Founded by Heather Hasson and Trina Spear to disrupt the traditional medical uniform market with better-designed scrubs.
  • Pre-IPO: Rapid DTC growth; revenue grew from $110.5M to $263M in 2020 (+138% YoY).
  • May 27, 2021: IPO on NYSE under ticker FIGS, raising approximately $462 million.
  • Post-IPO: Expanded product lines, built community around healthcare professionals, and navigated market volatility.

Interpretation: The founders' focus on "form and function" positioned FIGS as a category-defining brand in a historically fragmented, low-innovation market.

Data Limitation: Historical details derived from company filings and secondary sources as of August 2026; exact early financials may vary slightly in official 10-K reports.

Uncertainty Note: Forward-looking statements in earnings releases (e.g., guidance) are based on current expectations and subject to risks including macroeconomic conditions, tariffs, and consumer spending in healthcare.

Stock Performance & Company Financials

Yahoo Historical Data →

Historical Stock Performance (Fact - Annual Closing Prices & Returns)

Year Year-End Close (approx.) Annual % Change Notes
2025 $11.36 +83.52% Strong recovery year
2024 $6.19 -10.94% Challenging year
2023 $6.95 +3.27% Modest gain
2022 $6.73 -75.58% Significant decline post-IPO peak
2021 (partial) All-time high $50.10 (June 30, 2021)

Longer-term Returns (as of early August 2026 data, trailing periods):

Interpretation: The stock has shown high volatility typical of growth-oriented consumer/DTC names post-IPO but delivered strong recent performance amid improving fundamentals.

Data Limitation & Assumption: Performance figures are historical and do not include dividends (none paid). Returns calculated from available closing prices; exact current or intraday data excluded per guidelines. Past performance is not indicative of future results.

Company Financials (Fact - Key Metrics)

Metric TTM / Latest 2025 Annual Notes / YoY Change
Net Revenue ~$666M – $710M $631.1M +13.6% YoY (2025); Q2 2026: $196.6M (+28.8%)
Gross Profit ~$443.7M High gross margins (~67-75% in recent quarters)
Net Income ~$40.6M $34.25M Strong improvement; Q2 2026: $28.4M (14.4% margin)
EPS (Diluted) $0.22 Q2 2026 beat: $0.15 vs. est. $0.07
Adjusted EBITDA Margin Q2 2026: 18.6%; FY2026 guidance 14.8–15.0%
Active Customers 3.1 million (Q2 2026) Net revenue per active customer ~$229

Key Financial Highlights (Recent Quarters - Fact):

Data Limitation: Financial metrics sourced from earnings releases and analyst summaries as of August 2026. TTM figures are approximate aggregates. Full audited annual reports available on SEC EDGAR or company IR site. Guidance is management estimate and subject to change.

View Full Quarterly Results on IR Site → | Yahoo Finance Financials →

Analyst Ratings

MarketBeat Consensus →

Consensus Rating (Fact): Moderate Buy (as of early August 2026). Average rating score approximately 2.55 (on scale where lower = more bullish).

Breakdown Count
Strong Buy 1
Buy 4
Hold 6
Sell / Underperform 0

Recent Analyst Actions (Fact)

Consensus Price Target: Approximately $13.64 – $18.25 (range $4.50 low to $22.00 high). Implied upside varies significantly depending on current levels.

Interpretation: Analysts appear increasingly constructive following strong Q2 results and raised guidance, with several recent PT increases. However, a mix of Hold ratings indicates some caution on valuation or growth sustainability.

Data Limitation: Analyst ratings and targets are snapshots as of August 2026 and change frequently. They represent opinions, not guarantees. Always verify latest on financial platforms.

Customers & Competitors

Customers (Fact)

  • Primary: Healthcare professionals (physicians, nurses, medical staff) in the U.S. and internationally.
  • Channels: Direct-to-consumer via website and app; B2B partnerships; limited retail presence.
  • Key Metrics: 3.1 million active customers (Q2 2026); high repeat purchase rates and community engagement emphasized by company.
  • Growth Drivers: Brand community, product innovation, and healthcare industry tailwinds.

Interpretation: FIGS has built significant loyalty in a profession with recurring uniform needs, differentiating through lifestyle branding beyond basic functionality.

Company IR for Customer Metrics →

Competitors (Fact)

FIGS operates in a fragmented medical apparel market with both direct and adjacent competitors:

Competitor Positioning / Notes
Jaanuu Premium, fashion-forward scrubs; digital-first competitor
Barco Uniforms (Grey's Anatomy) Established medical apparel brand with professional styling
Careismatic Brands (Cherokee, Medelita, etc.) Larger multi-brand platform with traditional distribution
Fabletics Scrubs Activewear-performance scrubs; membership model
Landau, Superior Group Traditional wholesalers/uniform providers
Broader (e.g., Under Armour, Vuori) Adjacent lifestyle/activewear competitors

Interpretation: FIGS competes primarily on design, quality, and direct brand experience rather than price alone; traditional players have broader wholesale reach while newer DTC challengers focus on similar modern aesthetics.

Data Limitation: Competitor landscape is dynamic; list is not exhaustive. Market share data is limited in public sources. Customer demographics inferred from company descriptions.

Additional Resources for More Information